Drug Trial Radar · NCT01225731
A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003)
Last checked: Nov 20, 2026Latest source record: Feb 5, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
355
Actual
Start
Oct 25, 2010
Primary completion
Nov 4, 2011
Study completion Oct 24, 2012
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Oct 21, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a response-driven study of tildrakuzumab for the treatment of moderate to severe chronic plaque psoriasis. The primary study hypothesis is that one or more doses of tildrakizumab will be superior to placebo for the treatment of psoriasis.
Conditions
- Psoriasis
Interventions
tildrakizumabBiological
SC administration of tildrakizumab at assigned dose
PlaceboDrug
SC administration of Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With a Psoriasis Area and Severity Index (PASI)75 Response at Week 16Time frame: Week 16
- Number of Participants Experiencing Adverse EventsTime frame: Up to 72 weeks
- Number of Particpants Discontinuing Study Treatment Due to Adverse EventsTime frame: Up to 52 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.